These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15210503)

  • 1. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection.
    Greenough A; Alexander J; Burgess S; Bytham J; Chetcuti PA; Hagan J; Lenney W; Melville S; Shaw NJ; Boorman J; Coles S; Turner J; Pang F
    Arch Dis Child; 2004 Jul; 89(7):673-8. PubMed ID: 15210503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants.
    Greenough A; Alexander J; Boit P; Boorman J; Burgess S; Burke A; Chetcuti PA; Cliff I; Lenney W; Lytle T; Morgan C; Raiman C; Shaw NJ; Sylvester KP; Turner J
    Thorax; 2009 Jun; 64(6):490-5. PubMed ID: 19213770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective study of healthcare utilisation and respiratory morbidity due to RSV infection in prematurely born infants.
    Broughton S; Roberts A; Fox G; Pollina E; Zuckerman M; Chaudhry S; Greenough A
    Thorax; 2005 Dec; 60(12):1039-44. PubMed ID: 16227330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
    Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
    Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants.
    Broughton S; Bhat R; Roberts A; Zuckerman M; Rafferty G; Greenough A
    Arch Dis Child; 2006 Jan; 91(1):26-30. PubMed ID: 16188957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection.
    Greenough A; Cox S; Alexander J; Lenney W; Turnbull F; Burgess S; Chetcuti PA; Shaw NJ; Woods A; Boorman J; Coles S; Turner J
    Arch Dis Child; 2001 Dec; 85(6):463-8. PubMed ID: 11719328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
    McCormick J; Tubman R
    Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
    Paes B; Cole M; Latchman A; Pinelli J
    Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung function in prematurely born infants after viral lower respiratory tract infections.
    Broughton S; Sylvester KP; Fox G; Zuckerman M; Smith M; Milner AD; Rafferty GF; Greenough A
    Pediatr Infect Dis J; 2007 Nov; 26(11):1019-24. PubMed ID: 17984809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life.
    Forbes ML; Hall CB; Jackson A; Masaquel AS; Mahadevia PJ
    J Med Econ; 2010 Mar; 13(1):136-41. PubMed ID: 20128663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery.
    Leidy NK; Margolis MK; Marcin JP; Flynn JA; Frankel LR; Johnson S; Langkamp D; Simoes EA
    Pediatrics; 2005 Jun; 115(6):1536-46. PubMed ID: 15930214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.
    Boyce TG; Mellen BG; Mitchel EF; Wright PF; Griffin MR
    J Pediatr; 2000 Dec; 137(6):865-70. PubMed ID: 11113845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Populations at risk for developing respiratory syncytial virus and risk factors for respiratory syncytial virus severity: infants with predisposing conditions.
    Weisman L
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S33-7; discussion S37-9. PubMed ID: 12671450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.